ADTX Key Statistics, Chart & Performance
The current stock price of ADTX is 0.703 USD. In the past month the price decreased by -11.01%. In the past year, price decreased by -99.96%.
ADTX Technical Analysis
ADTX Financial Highlights
Over the last trailing twelve months ADTX reported a non-GAAP Earnings per Share(EPS) of -13217.71. The EPS increased by 81.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -357.97% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ADTX Forecast & Estimates
For the next year, analysts expect an EPS growth of -2096.63% and a revenue growth 1584.79% for ADTX
ADTX Ownership
ADTX Latest News, Press Relases and Analysis
ADTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.37 | 394.585B | ||
| AMGN | AMGEN INC | 16.68 | 202.372B | ||
| GILD | GILEAD SCIENCES INC | 17.01 | 188.186B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 119.469B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.8 | 82.007B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.77 | 42.275B | ||
| INSM | INSMED INC | N/A | 31.892B | ||
| NTRA | NATERA INC | N/A | 29.062B | ||
| BIIB | BIOGEN INC | 12.74 | 28.432B | ||
| INCY | INCYTE CORP | 13.62 | 21.405B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADTX
Company Profile
Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
Company Info
ADITXT INC
737 N. Fifth Street, Suite 200
Richmond VIRGINIA 94043 US
CEO: Amro Albanna
Employees: 26
Phone: 19094880844
ADITXT INC / ADTX FAQ
What does ADTX do?
Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
What is the current price of ADTX stock?
The current stock price of ADTX is 0.703 USD. The price increased by 7.99% in the last trading session.
Does ADITXT INC pay dividends?
ADTX does not pay a dividend.
How is the ChartMill rating for ADITXT INC?
ADTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists ADTX stock?
ADTX stock is listed on the Nasdaq exchange.
What is the market capitalization of ADTX stock?
ADITXT INC (ADTX) has a market capitalization of 393.68K USD. This makes ADTX a Nano Cap stock.
What is the Short Interest ratio of ADITXT INC (ADTX) stock?
The outstanding short interest for ADITXT INC (ADTX) is 19.16% of its float.